Nath LR, Murali M, Nair B. Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota. World J Gastrointest Oncol 2021; 13(12): 2219-2222 [PMID: 35070054 DOI: 10.4251/wjgo.v13.i12.2219]
Corresponding Author of This Article
Lekshmi R Nath, PhD, Assistant Professor, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Ponekkara P.O., Kochi 682041, Kerala, India. lekshmirnath@aims.amrita.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2219-2222 Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2219
Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota
Lekshmi R Nath, Maneesha Murali, Bhagyalakshmi Nair
Lekshmi R Nath, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India
Maneesha Murali, Bhagyalakshmi Nair, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India
Author contributions: Nath LR designed the draft; Murali M and Nair B performed a literature review; Nath LR and Nair B analyzed data; Nath LR and Murali M wrote the letter; Nath LR revised the paper.
Conflict-of-interest statement: The authors did not have any conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lekshmi R Nath, PhD, Assistant Professor, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Ponekkara P.O., Kochi 682041, Kerala, India. lekshmirnath@aims.amrita.edu
Received: May 31, 2021 Peer-review started: May 31, 2021 First decision: June 26, 2021 Revised: July 15, 2021 Accepted: November 5, 2021 Article in press: November 5, 2021 Published online: December 15, 2021 Processing time: 197 Days and 16.3 Hours
Abstract
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and one of the major causes of cancer-related death. The development of specific non-invasive or diagnostic markers from blood, urine and feces may represent a valuable tool for detecting HCC at an early stage. Biomarkers are considered novel potential targets for therapeutic intervention. It helps in the prediction of prognosis or recurrence of HCC, and also assist in the selection of appropriate treatment modality. We summarize the most relevant existing data about various biomarkers that play a key role in the progression of HCC.
Core Tip: Hepatocellular carcinoma (HCC) ranks fourth among the leading causes of cancer-related mortality. The development of specific noninvasive or diagnostic markers from blood, urine and feces may represent a valuable tool for detecting HCC at an early stage. Biomarkers help in the prediction of prognosis or recurrence, selection of appropriate treatment modality, and signify novel potential targets for therapeutic interventions. We summarize the most relevant existing data about various biomarkers involved in the progression of HCC.
